Class Action Alert for REGENXBIO Investors: Legal Steps and Timeline for Shareholders

Attention REGENXBIO Inc. Investors

The Gross Law Firm has issued a significant alert for shareholders of REGENXBIO Inc. (NASDAQ: RGNX) who may have experienced financial losses. If you purchased shares during the established class period, this information could be critical for your potential recovery.

Overview of the Class Action

According to recent notices, investors who acquired RGNX shares between February 9, 2022, and January 27, 2026, are encouraged to reach out to The Gross Law Firm regarding possible participation in the forthcoming class action lawsuit. A key aspect is that those interested in recovering damages do not need to be appointed as lead plaintiffs to benefit from any outcomes.

Allegations Against REGENXBIO

The allegations center around misleading information provided by REGENXBIO’s management regarding their product candidate RGX-111, a gene therapy aimed at treating severe Mucopolysaccharidosis Type I (commonly referred to as Hurler syndrome). The claim states the defendants made overly optimistic assertions about RGX-111’s trial success, drawing from favorable biomarker and safety data from the ongoing Phase I/II trial.

However, it was later revealed that while making these positive statements, the company concealed critical information regarding the efficacy and safety of RGX-111’s trial. The situation escalated dramatically following the FDA's announcement on January 28, 2026, indicating that a clinical hold had been placed on the RGX-111 therapy after a participant in the trial developed a serious intraventricular CNS tumor.

This development led to a rapid decline in the company's stock price; shares fell by approximately 17.8% in just one day—from $13.41 on January 27, 2026, to $11.01 the following day.

Important Deadlines

Shareholders interested in this class action have a crucial deadline approaching. Registration to partake in the class action must be completed by April 14, 2026. The Gross Law Firm has highlighted that those who register will benefit from a portfolio monitoring tool, which will keep them updated throughout the legal process.

Next Steps for Investors

If you believe you are eligible to participate, you can easily register through this link. It's worth noting that there is no financial obligation or cost involved in registering for this suit.

Why Choose Gross Law Firm?

The Gross Law Firm is recognized nationally for its work in protecting investor rights, especially those who have sustained losses due to corporate deceit and questionable practices. They have a commitment to supporting investors in regaining their financial losses resulting from misleading company disclosures.

The firm emphasizes that they seek to hold companies accountable for their actions and ensure that responsible business practices are followed.

If you have any inquiries or need further clarification about your investments in REGENXBIO or the steps involved in this class action, you can contact The Gross Law Firm directly:

- Address: 15 West 38th Street, 12th floor, New York, NY, 10018
- Email: [email protected]
- Phone: (646) 453-8903

In summary, if you invested in REGENXBIO during the specified period and faced losses, it’s crucial to act now to protect your rights as a shareholder. Staying informed and engaged is key to potentially reclaiming your investments.